311 results on '"Pietra, D."'
Search Results
2. ODP181 Diabetes Mellitus and Advanced Liver Fibrosis – is Cirrhosis Reversible and Who Should We Screen?
3. Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients
4. Secreted Mutant Calreticulins As Rogue Cytokines in Myeloproliferative Neoplasms
5. P984: MUTATIONAL PATTERNS IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)
6. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes
7. The JAK2 V617F mutation in patients with cerebral venous thrombosis
8. ODP181 Diabetes Mellitus and Advanced Liver Fibrosis – is Cirrhosis Reversible and Who Should We Screen?
9. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients
10. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms
11. Allelic imbalance in CALR somatic mutagenesis
12. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes
13. Mutations and prognosis in primary myelofibrosis
14. A Case of Fishy Smell-Fish Malodor Syndrome
15. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
16. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms
17. SUN-518 Graves’ Disease Newly Diagnosed in the Setting of Hypokalemic Periodic Paralysis in an HIV+ Patient
18. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome
19. Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation
20. SUN-518 Graves’ Disease Newly Diagnosed in the Setting of Hypokalemic Periodic Paralysis in an HIV+ Patient
21. Design for enhanced control of damage
22. The ‘GGCC’ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera
23. Using seismic isolation and energy dissipation to create earthquake-resilient buildings
24. Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis
25. Diet treatment of branched chain ketoaciduria studied by proton magnetic resonance spectroscopy
26. Cord blood in vitro expanded CD41+ cells: identification of novel components of megakaryocytopoiesis
27. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome
28. PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia
29. Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients
30. PS1458 RISK FACTORS AND OUTCOME OF ACUTE MYELOID LEUKEMIA SECONDARY TO POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT
31. CLINICAL AND MOLECULAR CHARACTERISTICS OF SRSF2-MUTATED NEOPLASMS
32. PF669 RUXOLITINIB TREATMENT AND RISK OF B-CELL LYMPHOMAS IN MYELOPROLIFERATIVE NEOPLASMS
33. PF535 CLINICAL AND MOLECULAR CHARACTERISTICS OF SRSF2-MUTATED NEOPLASMS
34. PF655 PROGNOSTIC RELEVANCE OF THE GENE EXPRESSION SIGNATURE IN PRIMARY AND SECONDARY MYELOFIBROSIS
35. Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project
36. Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC project
37. Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia
38. Driver mutations' effect in secondary myelofibrosis: An international multicenter study based on 781 patients
39. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
40. Germline RBBP6 mutations in familial myeloproliferative neoplasms
41. Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients
42. Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations
43. COLD-PCR and Innovative Microarray Substrates for Detection and Genotyping of MPL exon 10 W515 Substitutions
44. Germline RBBP6 mutations in familial myeloproliferative neoplasm
45. Severe Babesiosis in Long Island: Review of 34 Cases and Their Complications
46. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
47. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
48. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V817F)- negative myeloproliferative disorders
49. Tecniche vecchie, obiettivi nuovi: i quesiti lessicali
50. Un significante per tanti significati. I giovani nisseni
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.